Tubulysin analogs and methods for their preparation
申请人:PFIZER INC.
公开号:US10723727B2
公开(公告)日:2020-07-28
The present invention is directed to novel cytotoxic tubulysin analogs and derivatives, to antibody drug conjugates thereof, and to methods for using the same to treat medical conditions including cancer.
本发明涉及新型细胞毒性管胞素类似物和衍生物、其抗体药物共轭物以及用其治疗包括癌症在内的病症的方法。
CONFORMATIONALLY STABLE ANALOGS OF THE RESPONSE SELECTIVE C5A AGONIST EP67
申请人:Board of Regents of the
University of Nebraska
公开号:EP3267980A1
公开(公告)日:2018-01-17
TUBULYSIN ANALOGS AND METHODS FOR THEIR PREPARATION
申请人:Pfizer Inc.
公开号:EP3411371A1
公开(公告)日:2018-12-12
ANTI-PARASITIC IMMUNOLOGICAL COMPOSITIONS
申请人:Prommune, Inc.
公开号:US20210290761A1
公开(公告)日:2021-09-23
Anti-parasitic compounds and uses thereof. Compounds comprising a C-terminal peptide adjuvant conjugated to an N-terminal peptide antigen via a protease-cleavable linker, said peptide adjuvant comprising a peptide analog of C5a, wherein said peptide antigen comprises an antigenic epitope of a parasitic organism, such as
T. gondii
. Methods of therapeutic or prophylactic treatment of a parasitic infections.
[EN] CONFORMATIONALLY STABLE ANALOGS OF THE RESPONSE SELECTIVE C5A AGONIST EP67<br/>[FR] ANALOGUES À CONFORMATION STABLE DE L'AGONISTE EP67 DU FRAGMENT C5A À RÉPONSE SÉLECTIVE
申请人:UNIV NEBRASKA
公开号:WO2016145365A1
公开(公告)日:2016-09-15
Conformationally-stable peptide analogs of the response selective C5a agonist EP67 having the formula Tyr-Ser-Phe-Lys-Asp-Met-Xaa-(Xaa2)-(D-Ala)-Arg (SEQ ID NO:1), wherein Xaa is a modified proline residue or a residue substitution for proline, and Xaa2 is leucine or N-methyl leucine. The conformationally-stable peptides selectively bind and activate APCs without directly engaging/binding C5a receptor-bearing cells involved in pro-inflammatory activities of natural C5a. Compositions and methods of using the peptide analogs are also described.